Literature DB >> 1631893

Therapeutic efficacy of HI-6 in soman-poisoned marmoset monkeys.

H P van Helden1, H J van der Wiel, J de Lange, R W Busker, B P Melchers, O L Wolthuis.   

Abstract

The therapeutic efficacy of the oxime HI-6 against intoxication with the irreversible cholinesterase (ChE) inhibitor soman was tested in marmoset monkeys. Five out of six marmosets, intoxicated with 5 x LD50 soman and treated immediately with diazepam (0.2 mg.kg-1 iv) and 15 sec later with atropine (0.5 mg.kg-1 im) and HI-6 (50 mg.kg-1 im), survived for more than 24 hr. One of these animals died after 4 days. In the HI-6-treated marmosets blood ChE activity was inhibited at a rate slower than that in three animals treated similarly but with saline instead of HI-6. The latter marmosets died within 8 min after soman. HI-6 achieved its plasma peak 5 min after injection and was eliminated with a t1/2 of about 40 min. In a second experiment similarly treated marmosets were euthanized at 5 min (three saline-treated animals) or at 10 min (three HI-6-treated animals) after the soman intoxication to enable the determination of acetylcholinesterase (AChE) activities in diaphragm and brain tissue. In addition, in these animals blood AChE and butyrylcholine esterase (BuChE) activities were determined. Low AChE activities were encountered in diaphragms and brains. These levels were not significantly different between saline- and HI-6-treated marmosets. In vitro treatment with HI-6 at 40 min after soman still led to an increase of the AChE activity, which was significant in diaphragm, suggesting that postmortem AChE inhibition had occurred. The ratio of AChE to BuChE in blood was significantly enhanced in HI-6-treated animals, indicating that HI-6 preferentially reactivated AChE. It is concluded that (i) HI-6 is an effective treatment against soman poisoning in marmosets and (ii) AChE reactivation or protection by HI-6 contributed to the survival of the animals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1631893     DOI: 10.1016/0041-008x(92)90366-z

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

1.  In vitro oxime-induced reactivation of various molecular forms of soman-inhibited acetylcholinesterase in striated muscle from rat, monkey and human.

Authors:  J G Clement; N Erhardt
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

2.  Treatment of organophosphate poisoning in pigs: antidote administration by a new binary autoinjector.

Authors:  A Göransson-Nyberg; G Cassel; T Jeneskog; L Karlsson; R Larsson; M Lundström; S A Persson
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

3.  Non-reactivating effects of HI-6 on hippocampal neurotransmission.

Authors:  B P Melchers; A L van der Laaken; R W Busker; P L Bruijnzeel; H P Van Helden
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

4.  Comparison of several oximes on reactivation of soman-inhibited blood, brain and tissue cholinesterase activity in rats.

Authors:  T M Shih
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

5.  Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats.

Authors:  H P van Helden; H J van der Wiel; J J Zijlstra; B P Melchers; R W Busker
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

6.  The functional role of molecular forms of acetylcholinesterase in neuromuscular transmission.

Authors:  R W Busker; J J Zijlstra; H J van der Wiel; H P van Helden
Journal:  Neurochem Res       Date:  1994-06       Impact factor: 3.996

Review 7.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.